Diego F Munoz
Overview
Explore the profile of Diego F Munoz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trentham-Dietz A, Hunter Chapman C, Jayasekera J, Lowry K, Heckman-Stoddard B, Hampton J, et al.
JAMA
. 2024 Apr;
331(22):1947-1960.
PMID: 38687505
Importance: The effects of breast cancer incidence changes and advances in screening and treatment on outcomes of different screening strategies are not well known. Objective: To estimate outcomes of various...
2.
Serra F, Balseiro D, Monnet C, Randolfe E, Bignon A, Rustan J, et al.
Sci Data
. 2023 Nov;
10(1):841.
PMID: 38030629
Modern morphometric-based approaches provide valuable metrics to quantify and understand macroevolutionary and macroecological patterns and processes. Here we describe TriloMorph, an openly accessible database for morpho-geometric information of trilobites, together...
3.
Mangano M, Buatois L, Waisfeld B, Munoz D, Vaccari N, Astini R
Proc Biol Sci
. 2021 Feb;
288(1944):20202263.
PMID: 33529560
Trilobites, key components of early Palaeozoic communities, are considered to have been invariably fully marine. Through the integration of ichnological, palaeobiological, and sedimentological datasets within a sequence-stratigraphical framework, we challenge...
4.
Munoz D, Xu C, Plevritis S
Med Decis Making
. 2018 Mar;
38(1_suppl):89S-98S.
PMID: 29554473
We present a Monte Carlo simulation model that reproduces US invasive breast cancer incidence and mortality trends from 1975 to 2010 as a function of screening and adjuvant treatment. This...
5.
van den Broek J, van Ravesteyn N, Mandelblatt J, Cevik M, Schechter C, Lee S, et al.
Med Decis Making
. 2018 Mar;
38(1_suppl):112S-125S.
PMID: 29554471
Background: Collaborative modeling has been used to estimate the impact of potential cancer screening strategies worldwide. A necessary step in the interpretation of collaborative cancer screening model results is to...
6.
Munoz D, Plevritis S
Med Decis Making
. 2018 Mar;
38(1_suppl):32S-43S.
PMID: 29554464
Background: As molecular subtyping of breast cancer influences clinical management, the evaluation of screening and adjuvant treatment interventions at the population level needs to account for molecular subtyping. Performing such...
7.
Schackmann E, Munoz D, Mills M, Plevritis S, Kurian A
Fam Cancer
. 2012 Oct;
12(1):65-73.
PMID: 23086584
Women with BRCA1 or BRCA2 (BRCA1/2) mutations face difficult decisions about managing their high risks of breast and ovarian cancer. We developed an online tool to guide decisions about cancer...
8.
Sigal B, Munoz D, Kurian A, Plevritis S
Cancer Epidemiol Biomarkers Prev
. 2012 May;
21(7):1066-77.
PMID: 22556274
Background: Women with inherited mutations in the BRCA1 or BRCA2 (BRCA1/2) genes are recommended to undergo a number of intensive cancer risk-reducing strategies, including prophylactic mastectomy, prophylactic oophorectomy, and screening....
9.
Kurian A, Munoz D, Rust P, Schackmann E, Smith M, Clarke L, et al.
J Clin Oncol
. 2012 Jan;
30(5):497-506.
PMID: 22231042
Purpose: Women with BRCA1 or BRCA2 (BRCA1/2) mutations must choose between prophylactic surgeries and screening to manage their high risks of breast and ovarian cancer, comparing options in terms of...